BPC-157 is a synthetic peptide consisting of 15 amino acids, derived from a protein sequence originally identified in human gastric juice. In research settings, it has been studied primarily for its effects on tissue repair, with most evidence coming from animal models examining muscle, tendon, ligament, and bone healing.
This article walks through what BPC-157 is, how researchers think it works, and what the current body of evidence shows. It's educational, not medical advice.
The Quick Answer
BPC-157 is a synthetic 15 amino acid peptide derived from a protein originally identified in human gastric juice. Research, primarily in animal models, has examined its effects on muscle, tendon, ligament, and bone repair, with proposed mechanisms involving angiogenesis, growth factor signaling, and modulation of the nitric oxide pathway. Human evidence is limited. BPC-157 is not FDA approved; in April 2026 the FDA removed it from Category 2 and scheduled a Pharmacy Compounding Advisory Committee review for July 23–24, 2026 to evaluate it for the 503A bulks list.
The Origin Story
BPC stands for Body Protection Compound. The compound was first isolated in the early 1990s by a research group in Croatia led by Predrag Sikiric, who identified a protein in gastric juice that appeared to have protective effects on tissue. From that larger protein, researchers identified a 15 amino acid sequence that seemed to carry the activity. They called it BPC-157.
The full BPC-157 sequence as used in studies does not occur naturally in the human body. It is synthesized in a lab. So when you see BPC-157 described as “naturally occurring,” that's not quite right. The parent protein is naturally occurring. The peptide itself is a synthetic construct based on a sequence found within that protein.
How Peptides Work in the Body
To understand what researchers are studying when they study BPC-157, it helps to understand what peptides do generally.
Peptides are short chains of amino acids. Proteins are long chains of amino acids. The difference is mostly length. Peptides typically run from 2 to about 50 amino acids. Anything longer is generally called a protein.
In the body, peptides function as signaling molecules. They bind to receptors on cells and trigger specific responses. Insulin is a peptide. So is oxytocin. So are growth hormone-releasing peptides. Each one carries a specific instruction to specific cells.
This is the framework researchers use when studying BPC-157. The hypothesis is that this particular 15 amino acid sequence carries instructions related to tissue repair.
What the Research Has Identified
Across roughly three decades of preclinical research, investigators have identified several biological pathways that BPC-157 appears to influence in animal models.[1]
Angiogenesis
The formation of new blood vessels. When tissue is damaged, blood supply to the area becomes critical — oxygen, nutrients, and immune cells all travel through blood vessels. Animal studies suggest BPC-157 may upregulate this process, particularly in tissues that don’t get much blood flow to begin with, like tendons.
Growth Factor Signaling
Animal studies have shown changes in growth hormone receptor expression and IGF-1 pathway activity in tissues treated with BPC-157. These pathways are involved in collagen synthesis and structural tissue remodeling. Collagen is the protein your tendons and ligaments are mostly made of, which is part of why this pathway interests recovery researchers.
Inflammatory Modulation
Inflammation is necessary for healing. It is also damaging when it persists or runs unchecked. Animal models suggest BPC-157 may shift the inflammatory response in a way that supports repair without amplifying tissue damage, though the exact mechanism is still being worked out.
Nitric Oxide Pathway
Nitric oxide plays roles in blood vessel function, neurotransmission, and tissue protection. Some BPC-157 research has examined effects on this system, particularly in models of organ injury.[2]
Researchers describe BPC-157 as having “pleiotropic” activity, meaning it appears to act on multiple biological systems at once. Most compounds in clinical use are designed to hit a single, specific target. The breadth of BPC-157's apparent activity is part of what has made it interesting to researchers and, separately, part of what makes it hard to study in a clean way.
The Animal Research Base
The preclinical literature on BPC-157 is substantial. A 2025 systematic review identified 36 published studies on BPC-157 spanning 1993 to 2024. Thirty-five were preclinical. One was clinical.[2]
In animal models, BPC-157 has been examined in scenarios including:
- Achilles tendon transection and repair
- Medial collateral ligament injury
- Muscle crush injury
- Bone fracture healing
- Gastrointestinal ulcers and inflammatory bowel models
- Traumatic brain injury models
Across these studies, treated animals have generally shown faster functional recovery, more organized collagen deposition, and better structural outcomes than untreated controls. The findings are consistent across multiple research groups and multiple injury models, which is part of why the compound has generated sustained scientific interest.
That consistency in animal data is real. It's also where the conversation about BPC-157 usually stops, and that's a problem, because animal data and human data are not the same thing.
What's Known in Humans
This is where the picture gets a bit thinner. As of 2026, only three small pilot studies on BPC-157 have been published in humans, all conducted by the same research group in Florida.
2021 chart review. A retrospective chart review of 17 patients who received intra-articular BPC-157 injections for various types of knee pain. Of those followed up, a portion reported pain relief lasting more than six months. There was no placebo group. The study was conducted at a clinic that offers the treatment.[3]
2024 pilot study. A pilot study examining intravesical BPC-157 in women with interstitial cystitis, a chronic bladder condition. The patients reported symptom improvement. Again, no placebo group, small sample size.[4]
2025 safety study. An intravenous safety study in two healthy adults receiving doses up to 20 mg. No adverse cardiac or renal effects were reported.[5]
A formal Phase 1 trial of BPC-157 was registered with the FDA in 2015 to study safety and pharmacokinetics in 42 volunteers. The trial was cancelled in 2016. No results were ever published.[2]
The animal evidence is large, consistent, and mechanistically interesting. The human evidence is concentrated within a small group of researchers. BPC-157 is not currently approved by the FDA for any medical use, and its legal status for compounding in the United States is restrictive.[6]
What Researchers Are Watching
Several areas of BPC-157 research are still active. The most-studied applications relate to musculoskeletal recovery, particularly tendon and ligament healing, where the preclinical signal has been strongest. Gastrointestinal applications, given the compound's origin from a gastric protein, are another area of theoretical interest. Some early work has examined neuroprotective effects, but this remains in early stages.
The Bottom Line
BPC-157 is a synthetic 15 amino acid peptide that, in animal studies, appears to influence multiple biological systems involved in tissue repair, including angiogenesis, growth factor signaling, and inflammatory response. The animal research is consistent and spans three decades.
The human research is limited to a handful of small pilot studies, none of which were placebo-controlled. BPC-157 is not FDA-approved, and its regulatory status in the United States is restrictive.
For people interested in the science of recovery and tissue repair, BPC-157 is a genuinely interesting case study in how peptide signaling works. For people considering it as a personal therapy, the gap between what's been shown in animals and what's been confirmed in humans is the most important thing to understand.
Common Questions
Have questions about peptide therapy?
We’re happy to discuss what the evidence supports and what your options actually are.
Keep Reading
Last updated May 19, 2026.
References
- Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021;12:627533.
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8-13.
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine. 2024;30(10):12-17.
- Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine. 2025. PMID: 40131143.
- U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A. January 2025.